Edition:
United States

Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.45USD
17 Feb 2018
Change (% chg)

$0.01 (+2.10%)
Prev Close
$0.44
Open
$0.44
Day's High
$0.47
Day's Low
$0.44
Volume
631,544
Avg. Vol
633,570
52-wk High
$0.84
52-wk Low
$0.30

Latest Key Developments (Source: Significant Developments)

Hemispherx Biopharma says ‍New Development to Provide Consistent Enzyme Product, Uninterrupted Production Of Ampligen
Thursday, 11 Jan 2018 08:30am EST 

Jan 11 (Reuters) - Hemispherx Biopharma Inc ::HEMISPHERX BIOPHARMA - ‍NEW DEVELOPMENT CAN PROVIDE CONSISTENT ENZYME PRODUCT,UNINTERRUPTED PRODUCTION OF AMPLIGEN,IN LONG RUN,REDUCE PRODUCTION COSTS​.  Full Article

Hemispherx Biopharma posts Q3 ‍net loss $1.3 mln vs $2.9 mln last year
Wednesday, 15 Nov 2017 08:30am EST 

Nov 15 (Reuters) - Hemispherx Biopharma Inc :Hemispherx Biopharma announces corporate progress and financial results for the nine months ended September 30, 2017.Hemispherx Biopharma Inc qtrly ‍net loss was $1.3 million compared to $2.9 million​.  Full Article

Hemispherx Biopharma says files for resale of 5.4 mln shares of common stock, offered for sale by selling stockholders
Friday, 29 Sep 2017 05:42pm EDT 

Sept 29 (Reuters) - Hemispherx Biopharma Inc :Hemispherx Biopharma - files for resale of of 5.4 million shares of common stock, offered for sale by selling stockholders - SEC Filing‍​.  Full Article

Hemispherx Biopharma Co's board has reviewed financial condition of company and anticipated needs of company to pursue its goals
Tuesday, 29 Aug 2017 09:07am EDT 

Aug 29 (Reuters) - Hemispherx Biopharma Inc :Co's board has reviewed financial condition of company and anticipated needs of company to pursue its goals.Hemispherx Biopharma - Determined that co will need to find additional funding sources and reduce on-going expenses to cover expenses and pursue goals.Hemispherx Biopharma - On Aug 22, board authorized executive compensation deferral plan, employee pay reduction plan, directors compensation deferral plan.  Full Article

Hemispherx Biopharma announces quarterly loss per share $0.11
Monday, 15 May 2017 05:24pm EDT 

May 15 (Reuters) - Hemispherx Biopharma Inc :Hemispherx Biopharma announces financial results for the three months ended March 31, 2017.Quarterly loss per share $0.11.Hemispherx Biopharma- Have begun to generate and can now reasonably project growing future revenues from newly manufactured lots of ampligen for 2017.Hemispherx Biopharma - Bridge loan established on May 12 to assist in funding expenses of manufacturing Ampligen to generate revenues for 2017, 2018.Hemispherx Biopharma Inc - Cash, cash equivalents and marketable securities were about $3.7 million at March 31, 2017 versus $5.9 million as of Dec 31, 2016.  Full Article

Hemispherx Biopharma announces identification of high responder patient subgroup from Ampligen Phase III trial
Monday, 31 Oct 2016 08:30am EDT 

Hemispherx Biopharma Inc :Hemispherx Biopharma announces identification of high responder patient subgroup from Ampligen phase III trial in patients with CFS/ME.  Full Article

Sabby Management LLC reports 6.92 pct passive stake in Hemispherx Biopharma
Thursday, 1 Sep 2016 01:52pm EDT 

Hemispherx Biopharma Inc :Sabby Management LLC reports 6.92 percent passive stake in Hemispherx Biopharma Inc as of August 31 - Sec Filing.  Full Article

Hemispherx says focusing on commercial success by seeking co-development partners
Monday, 15 Aug 2016 05:03pm EDT 

Hemispherx Biopharma Inc : Hemispherx biopharma announces financial results for the six months ended june 30, 2016 .Says now focusing on commercial success by seeking co-development partners.  Full Article

Hemispherx, Avrio strike contract manufacturing deal
Wednesday, 27 Jul 2016 08:30am EDT 

Hemispherx Biopharma Inc : Agreement with Avrio Biopharmaceuticals, Irvine California, to serve as additional contract manufacturer of Hemispherx's Ampligen . Hemispherx Biopharma reaches agreement with Avrio Biopharmaceuticals for the accelerated production of Ampligen .Agreement with Avrio should allow Hemispherx to replenish its Ampligen/Rintatolimod inventory.  Full Article

Hemispherx Biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation
Wednesday, 8 Jun 2016 11:53am EDT 

Hemispherx Biopharma : Hemispherx biopharma enters into settlement agreements dismissing all pending shareholder derivative litigation, resolving disputes with insurance carriers, and obtaining commitments of $3.5 million in payments to company . Two pending disputes in mediation with company insurers have also been settled with a commitment to pay $3,500,000 to company .All four derivative cases have now been settled, subject to final court approval.  Full Article

BRIEF-Hemispherx Enters Sale/Leaseback Agreement For NJ Development And Production Facility

* HEMISPHERX ENTERS INTO SALE/LEASEBACK AGREEMENT FOR NJ DEVELOPMENT AND PRODUCTION FACILITY